Controlling Polysaccharide Molecular Weight through High-Shear Processing

In this webinar, we will explore the critical role of controlling polysaccharide molecular weight in the production of conjugate vaccines. The session will delve into the use of high-shear processing, specifically the Dyhydromatics® ShearJet® HL60, to achieve precise degradation of polysaccharides. We will discuss how variations in concentration and the number of passes through the high-shear processor impact the final product, characterized using size-exclusion chromatography with multi-angle light scattering (SEC-MALS). This technique ensures a more uniform product with reduced molecular weight and polydispersity, enhancing reproducibility and product quality.

Key Learning Objectives:

• Understand the Importance of Polysaccharide Molecular Weight Control: Learn why controlling the molecular weight of polysaccharides is crucial for the consistency and potency of conjugate vaccines.
• Explore High-Shear Processing Techniques: Gain insights into the mechanical degradation of polysaccharides using the Dyhydromatics® ShearJet® HL60 and how it compares to chemical hydrolysis.
• Analyze the Impact of Processing Parameters: Discover how different concentrations and the number of passes through the high-shear processor affect the molecular weight and polydispersity of polysaccharides.
• Characterize Polysaccharides with SEC-MALS: Understand the principles and advantages of using SEC-MALS for accurate characterization of polysaccharide molecular weight and polydispersity.

Who Should Attend:

• Biotech and Vaccine Industry Professionals: Individuals involved in the research, development, and production of conjugate vaccines.
• Analytical Chemists and Biochemists: Professionals interested in the characterization and analysis of polysaccharides and other polymers.
• Process Engineers:Those looking to optimize high-shear processing techniques for improved product quality and consistency.
• Quality Control Specialists: Individuals responsible for ensuring the reproducibility and quality of vaccine products.

Presenter: Andrew Lees, Ph.D (Fina Biosolutions)

Andrew Lees, Ph.D., is the founder and CEO of Fina Biosolutions, a company specializing in conjugate vaccine research and development. With over 30 years of experience in conjugation chemistry, he is renowned for developing the CDAP conjugation method. Dr. Lees has significantly contributed to the field of vaccine development and polysaccharide conjugation.